About LegoChem BiosciencesLegoChem Biosciences is a biopharmaceutical company focusing on the development of next generation cancer therapeutics utilizing its proprietary ADC platform technology ‘ConjuAll™’.
CEO: Yong Zu Kim
CTO: Yeong Soo Oh
CBO: Jeiwook Chae
CFO: Sejin Park
8 articles with LegoChem Biosciences
LegoChem Biosciences, Inc. (“LCB”) (KOSDAQ:141080), based in Daejeon, South Korea, announced today a worldwide license agreement with Iksuda Therapeutics (“Iksuda”) for the development and commercialization of LCB73, a CD19-targeted ADC candidate for hematological tumors. Under the terms of the agreement, Iksuda will make an upfront payment of USD 5 million and LCB is eligible to receive development, regulator
LegoChem Biosciences and Iksuda Enter into a Multi-Target Research Collaboration and License Agreement for the Development of Antibody-Drug Conjugates
LegoChem Biosciences, Inc. (“LCB”) (KOSDAQ:141080), based in Daejeon, South Korea, announced today that it has entered a research collaboration and license agreement with Iksuda Therapeutics (“Iksuda”) for the development of antibody-drug conjugates in oncology.
LegoChem Biosciences and Takeda Enter into a Multi-Target Research Collaboration and License Agreement for the Development of Antibody-Drug Conjugates in Immuno-Oncology
Takeda gains certain rights to LCB’s antibody-drug conjugate technology, ConjuAll, including LCB’s proprietary linker and conjugation platform, to research, develop and commercialize targeted immuno-oncology therapeutics.
Geom Therapeutics To Develop And Commercialize LegoChem Biosciences' Novel Beta Lactamase Inhibitors For Treating Gram-Negative Infections
LegoChem Biosciences Enters Into Research Licensing Agreement With Takeda To Develop Next-Generation Antibody-Drug Conjugate Candidates
Nordic Nanovector And LegoChem Biosciences Enter Collaboration To Develop Novel Antibody-Drug Conjugates (ADCS) Targeting Leukemias